Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389327 | 0.82 | HPGD (0.41) | KMT2APOLBMEN1GAATSHR | |
| SCHEMBL10755881 | 0.80 | KMT2A (0.50) | KMT2APOLBPADI4FPR2MEN1 | |
| SCHEMBL21389277 | 0.79 | GAA (0.38) | KMT2AGAAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL21389146 | 0.78 | GAA (0.37) | KMT2AGAAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL21389177 | 0.77 | GAA (0.36) | POLBGAAALDH1A1L3MBTL1 | |
| SCHEMBL21389194 | 0.77 | GAA (0.36) | KMT2AGAAALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL12646807 | 0.77 | KMT2A (0.53) | KMT2APOLBPADI4FPR2MEN1 | |
| SCHEMBL21389123 | 0.77 | GAA (0.36) | KMT2AMEN1GAAALDH1A1L3MBTL1 | |
| SCHEMBL26752781 | 0.76 | GAA (0.35) | KMT2APOLBGAATSHRALDH1A1 | |
| SCHEMBL21384318 | 0.76 | ALDH1A1 (0.49) | KMT2APOLBGAAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | KMT2A 3040/4885POLB 4729/4885PADI4 4433/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | KMT2A 2741/4885POLB 4782/4885PADI4 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.